LB1908
Gastric, Pancreatic, and Colorectal Cancers
Key Facts
About Legend Biotech
Legend Biotech is a leader in the development of innovative cell therapies, with a primary focus on treating hematologic malignancies and solid tumors. Its landmark achievement is the development and commercialization of CARVYKTI, a BCMA-directed CAR-T therapy approved for relapsed/refractory multiple myeloma, which it co-develops and co-commercializes with Janssen Biotech, Inc. The company leverages its integrated cell therapy platform to build a diversified pipeline, including allogeneic and armored CAR-T candidates, and maintains strategic R&D operations in the U.S., China, and Europe.
View full company profile